Total Payments
$1.4M
2024 Payments
$121,954
Companies
67
Transactions
1,601
Medicare Patients
6,695
Medicare Billing
$971,695
Payment Breakdown by Category
Other$1.1M (75.4%)
Travel$210,649 (15.1%)
Consulting$92,357 (6.6%)
Food & Beverage$40,963 (2.9%)
Education$871.64 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 395 | 73.4% |
| Travel and Lodging | $210,649 | 373 | 15.1% |
| Consulting Fee | $92,357 | 36 | 6.6% |
| Food and Beverage | $40,963 | 743 | 2.9% |
| Honoraria | $25,925 | 10 | 1.9% |
| Long term medical supply or device loan | $1,131 | 12 | 0.1% |
| Education | $871.64 | 32 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | $199,654 | 186 | $0 (2024) |
| Amgen Inc. | $147,578 | 124 | $0 (2023) |
| Celgene Corporation | $134,325 | 122 | $0 (2024) |
| TESARO, Inc. | $130,205 | 126 | $0 (2019) |
| Merck Sharp & Dohme LLC | $118,054 | 124 | $0 (2024) |
| Daiichi Sankyo Inc. | $95,901 | 70 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $88,280 | 71 | $0 (2024) |
| Incyte Corporation | $77,899 | 67 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $65,328 | 38 | $0 (2024) |
| Gilead Sciences, Inc. | $51,144 | 36 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $121,954 | 121 | Daiichi Sankyo Inc. ($28,724) |
| 2023 | $266,496 | 223 | Daiichi Sankyo Inc. ($48,485) |
| 2022 | $182,190 | 149 | Incyte Corporation ($30,643) |
| 2021 | $96,221 | 88 | PUMA BIOTECHNOLOGY, INC. ($19,141) |
| 2020 | $79,593 | 47 | Puma Biotechnology, Inc. ($36,343) |
| 2019 | $192,561 | 210 | Puma Biotechnology, Inc. ($58,209) |
| 2018 | $204,726 | 343 | TESARO, Inc. ($54,651) |
| 2017 | $255,749 | 420 | TESARO, Inc. ($62,446) |
All Payment Transactions
1,601 individual payment records from CMS Open Payments — Page 1 of 65
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $31.78 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Oncology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,283.00 | General |
| Category: Hematology | ||||||
| 11/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $124.10 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Incyte Corporation | MONJUVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,480.00 | General |
| Category: Oncology | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,640.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,280.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $654.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $388.96 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $327.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $209.06 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology | ||||||
| 10/22/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Travel and Lodging | In-kind items and services | $894.54 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $4.97 | General |
| Category: Hematology | ||||||
| 10/07/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,680.00 | General |
| Category: Oncology | ||||||
| 10/07/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Travel and Lodging | In-kind items and services | $619.72 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,741 | 4,024 | $1.3M | $264,892 |
| 2022 | 13 | 1,657 | 4,005 | $1.3M | $264,272 |
| 2021 | 15 | 1,788 | 4,161 | $1.3M | $258,284 |
| 2020 | 12 | 1,509 | 3,380 | $1.0M | $184,247 |
Total Patients
6,695
Total Services
15,570
Medicare Billing
$971,695
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 590 | 1,511 | $831,050 | $165,261 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 108 | 179 | $133,355 | $29,196 | 21.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 113 | 113 | $120,345 | $23,091 | 19.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 612 | 1,717 | $35,480 | $14,347 | 40.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 95 | 169 | $63,375 | $13,738 | 21.7% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 15 | 75 | $36,825 | $6,918 | 18.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 69 | 70 | $12,320 | $5,028 | 40.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 71 | 72 | $7,776 | $2,491 | 32.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 13 | 13 | $23,517 | $2,206 | 9.4% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 17 | 41 | $14,760 | $1,292 | 8.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 25 | 29 | $14,935 | $866.53 | 5.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 35 | $9,625 | $455.94 | 4.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 565 | 1,630 | $896,500 | $183,390 | 20.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 131 | 131 | $139,515 | $27,195 | 19.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 88 | 145 | $108,025 | $23,968 | 22.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 65 | 117 | $43,875 | $9,934 | 22.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 586 | 1,693 | $33,860 | $4,990 | 14.7% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 64 | 64 | $11,264 | $4,383 | 38.9% |
| 99195 | Drawing of blood for a medical problem | Office | 2022 | 14 | 42 | $20,622 | $4,010 | 19.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 72 | 72 | $7,776 | $2,489 | 32.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 11 | 11 | $19,899 | $1,744 | 8.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 27 | 38 | $19,570 | $1,143 | 5.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 30 | $8,250 | $401.10 | 4.9% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2022 | 11 | 14 | $2,254 | $381.37 | 16.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 12 | 18 | $2,610 | $242.27 | 9.3% |
About Dr. Francis Arena, MD
Dr. Francis Arena, MD is a Internal Medicine healthcare provider based in Lake Success, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1699760132.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Francis Arena, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $121,954 received in 2024. These payments were reported across 1,601 transactions from 67 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Arena has provided services to 6,695 Medicare beneficiaries, totaling 15,570 services with total Medicare billing of $971,695. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Lake Success, NY
- Active Since 09/12/2005
- Last Updated 07/27/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1699760132
Products in Payments
- ZEJULA (Drug) $134,323
- KEYTRUDA (Biological) $117,866
- Abraxane (Drug) $112,048
- Nerlynx (Drug) $106,127
- LIBTAYO (Biological) $103,161
- NERLYNX (Drug) $91,867
- Enhertu (Drug) $88,646
- ENHERTU (Biological) $75,638
- MONJUVI (Drug) $75,450
- Vectibix (Biological) $74,243
- BRAFTOVI (Drug) $55,285
- XGEVA (Biological) $55,192
- Trodelvy (Drug) $46,083
- Orserdu (Drug) $43,525
- REBLOZYL (Biological) $43,230
- SIR-Spheres Microspheres (Device) $23,082
- KRAZATI (Drug) $14,990
- Prolia (Biological) $9,467
- Kadcyla (Biological) $9,392
- SOLIRIS (Drug) $7,313
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Lake Success
Dr. Bradley Morganstern, M.d, M.D
Internal Medicine — Payments: $80,254
Internal Medicine $80,254
Anna Kurzyna-Solinas, Md, MD
Internal Medicine — Payments: $8,761
Internal Medicine $8,761
Linda Tepper, Md, MD
Internal Medicine — Payments: $3,117
Internal Medicine $3,117
Brian Feingold, Md, MD
Internal Medicine — Payments: $1,752
Internal Medicine $1,752
Dr. Mitchell Locke, Md, MD
Internal Medicine — Payments: $1,337
Internal Medicine $1,337
Henry Vuong, M.d, M.D
Internal Medicine — Payments: $1,223
Internal Medicine $1,223